Base metal and telecom stocks help S&P/TSX composite rise more than 100 points
The S&P/TSX composite index was up 104.37 points at 27,879.60.
In New York, the Dow Jones industrial average was up 445.57 points at 44,420.66. The S&P 500 index was up 53.28 points at 6,426.73, while the Nasdaq composite was up 208.56 points at 21,593.96.
The Canadian dollar traded for 72.65 cents US compared with 72.54 cents US on Monday.
The September crude oil contract was down 17 cents US at US$63.79 per barrel.
The December gold contract was down US$13.50 at US$3,391.20 an ounce.
---
This report by The Canadian Press was first published Aug. 12, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
26 minutes ago
- The Market Online
MediPharm lays out the implications for possible new U.S. cannabis rescheduling
MediPharm Labs states it is positioned for potential U.S. cannabis rescheduling, having completed FDA site registration and filed a Drug Master File for CBD API Rescheduling cannabis to Schedule III would enable expanded medical research and access programs in the U.S., similar to those in Canada, Australia, and Germany The company will release its Q2 2025 financial results before markets open on Thursday, August 14, 2025, continuing its commitment to transparency and growth MediPharm Labs stock (TSX:LABS) last traded at $0.07 MediPharm Labs (TSX:LABS) shared its insights into its U.S. FDA site registration and strategic readiness in light of the potential federal rescheduling of cannabis in the United States. This content has been prepared as part of a partnership with MediPharm Labs Corp. and is intended for informational purposes only. Recent communications from the U.S. federal government and widespread media coverage suggest that the administration is actively reviewing the reclassification of cannabis from a Schedule I to a Schedule III controlled substance. This shift would mark a significant milestone in federal cannabis policy, recognizing its medical benefits and unlocking new pathways for research and patient access. Implications of rescheduling cannabis If cannabis is reclassified as a Schedule III drug: It would formally acknowledge its medical utility at the federal level Researchers in the U.S. would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers currently imposed by Schedule I classification The move could pave the way for expanded medical cannabis programs similar to those in Canada, Australia, and Germany Cannabis businesses would benefit from tax relief under Section 280E, which currently penalizes Schedule I and II substance handlers MediPharm's unique positioning MediPharm Labs stands out as one of the few companies globally—and the only publicly listed cannabis-focused firm in North America—with a comprehensive suite of regulatory approvals and infrastructure to capitalize on this potential shift: The company has successfully completed the process of foreign drug manufacturing site registration with the U.S. FDA, including a week-long inspection that granted it the authority to produce, label, test, and release pharmaceutical-grade cannabis products MediPharm has filed a Drug Master File with the FDA for its CBD active pharmaceutical ingredient (API), an important step for enabling late-stage clinical trials and finished dose product development It has already shipped cannabis API and products to the U.S. for research purposes, including a National Institutes of Health-funded clinical trial—an achievement made possible through FDA registration and DEA-issued import permits With these credentials, MediPharm sees itself in a stable position to support the anticipated surge in U.S.-based cannabis research and potential new medical access programs. The company's purpose-built, FDA-audited facility in Canada is one of only a handful worldwide capable of meeting the stringent standards required for pharmaceutical cannabis production. MediPharm Labs continues to uphold its pharmaceutical licenses and remains committed to serving researchers and patients with its brew of cannabinoid products. The company continues to watch developments in U.S. cannabis policy, ready to expand its footprint in the American market. The company plans to release its Q2 financial results for the three and six months ended June 30, 2025, before markets open on Thursday, August 14, 2025. MediPharm develops and manufactures pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products. MediPharm Labs stock (TSX:LABS) last traded at $0.07. Though up 25.00 per cent since the year began, the stock has also climbed 7.14 per cent since this time last year. Join the discussion: Find out what the Bullboards are saying about MediPharm Labs and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
The Market Online
26 minutes ago
- The Market Online
Rate-Cut Fever Lifts TSX Futures Higher
TSX futures climbed Wednesday, riding the high from yesterday's record close as cooler U.S. inflation stoked bets the Fed will pull the trigger on a September rate cut. Market Numbers (Futures) TSX : Up ( 0.16%) 27,841.89TSXV: Up (0.76%) 793.24DOW: Up (0.28%) 44,682.00NASDAQ: Up (0.24%) 23,995.00 FTSE: Up (0.16%) 9,162.81 In the Headlines: Liberals are cranking up the investor charm offensive—touring the country ahead of a fall economic update, promising 'certainty' to spark billions in long-term projects, from housing to ports. And Air Canada's flight attendants just dropped a 72-hour strike notice—setting a Saturday walkout in motion and leaving market-watchers bracing for chaos in Canada's skies. Currencies Update: (Futures) The Canadian dollar nudged higher by 0.10% against the greenback to USD72.75, slipped 0.24% versus the euro, while Bitcoin ripped 1.73% to hover at CDN$165,703.08 Commodities: (Futures) Natural Gas: Up (0.43%), 2.82WTI: Down (0.40%), 62.91Gold: Up (0.30%), 3,356.48 Copper: Up (0.07%) 6.06 To stay up-to-date on all of your market news head to Join the discussion: Find out what everybody's saying check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here
Globe and Mail
26 minutes ago
- Globe and Mail
TD SYNNEX Is Named NetApp North America Distributor of the Year for FY'25
TD SYNNEX (NYSE:SNX), a leading global distributor and solutions aggregator, today announced it has been named NetApp's North America Distributor of the Year for FY'25, recognizing the distributor that drives significant year-over-year (YoY) growth in their NetApp partner ecosystem while exhibiting demonstrated value in operations, sales and technical enablement, marketing, and financial services. The North America Partner Awards winners have exemplified NetApp's goal of being customer-centric and understanding and selling NetApp solutions across its cloud, flash, and NetApp Keystone® portfolios. This is the second consecutive year TD SYNNEX has earned this distinction from NetApp, and the achievement builds upon the company's recognition as NetApp's Distributor of the Year for FY'25 in EMEA. 'Being honored again as NetApp's North America Distributor of the Year is a testament to the exceptional dedication, expertise and passion of our teams,' said Jessica Yeck, Senior Vice President, AI Data and Apps at TD SYNNEX. 'This recognition reflects our ability to consistently deliver innovative, high-impact solutions to customers across North America. We are grateful to our partners and to NetApp for their collaboration, and we look forward to building on this momentum to fuel even greater success together.' 'With enterprise AI adoption accelerating, we're at an exciting crossroads where solution providers can shape the next wave of technological innovation,' said Jenni Flinders, Senior Vice President, Worldwide Partner Organization at NetApp. 'I want to congratulate TD SYNNEX on being named Distributor of the Year. Their partnership is integral to NetApp's success as we work together to give customers the confidence they need to navigate the era of intelligence.' For the full list of NetApp North America Partner Awards for FY'25, read the NetApp press release. To learn more about TD SYNNEX's NetApp solutions and offerings, visit About TD SYNNEX TD SYNNEX (NYSE: SNX) is a leading global distributor and solutions aggregator for the IT ecosystem. We are an innovative partner helping more than 150,000 customers in 100+ countries to maximize the value of technology investments, demonstrate business outcomes and unlock growth opportunities. Headquartered in Clearwater, Florida, and Fremont, California, TD SYNNEX's 23,000 co-workers are dedicated to uniting compelling IT products, services and solutions from 2,500+ best-in-class technology vendors. Our edge-to-cloud portfolio is anchored in some of the highest-growth technology segments including cloud, cybersecurity, big data/analytics, AI, IoT, mobility and everything as a service. TD SYNNEX is committed to serving customers and communities, and we believe we can have a positive impact on our people and our planet, intentionally acting as a respected corporate citizen. We aspire to be a diverse and inclusive employer of choice for talent across the IT ecosystem. For more information, visit follow our newsroom or follow us on LinkedIn, Facebook and Instagram. Copyright 2025 TD SYNNEX Corporation. All rights reserved. TD SYNNEX, the TD SYNNEX Logo, and all other TD SYNNEX company, product and services names and slogans are trademarks of TD SYNNEX Corporation. Other names and trademarks are the property of their respective owners. NETAPP, the NETAPP logo, and the marks listed at are trademarks of NetApp, Inc.
